Valproate-induced reversible cognitive decline presenting as dementia and associated clinical features: A literature review

Valproic acid (VPA) is an established, widely used broad-spectrum anti-seizure medication (ASM). Its therapeutic effect was serendipitously observed when it was used as a vehicle for other compounds being screened for anti-seizure activity in 1962 [1]. It was first marketed in France as an ASM in 1967 and approved by the FDA in 1978 [2]. Its use is widespread, being licensed for both focal and generalised epilepsy [3], and it has been used in migraine prophylaxis as well as in the treatment of bipolar disorders.
Source: Seizure: European Journal of Epilepsy - Category: Neurology Authors: Tags: Review Source Type: research